I'm guessing that as soon as the repatriation of funds combined with lower interest rates takes effect that the majority of mid-cap and large Bio's disappear.
Big Pharma has no other choice. Let's hope the Fed doesn't crowd everyone out of the Bond Markets this year.
Market Data 
Markets 
AI
